Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Mok (Perth, Australia), A. García-Uceda Juárez (Rotterdam, Netherlands), M. Kemner-Van De Corput (Rotterdam, Netherlands), N. Feyaerts (Leuven, Belgium), T. Rosenow (Perth, Australia), C. De Boeck (Leuven, Belgium), S. Stick (Perth, Australia), H. Tiddens (Rotterdam, Netherlands). The effect of CFTR modulators on CT outcomes in cystic fibrosis. 2128

Member's Comments

No comment yet.

Related content which might interest you: Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 Examining the effects of the Gly551Asp mutation on CT outcomes in children with cystic fibrosis Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Atypical cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38 Year: 2006 CFTR: cystic fibrosis and beyond Source: Eur Respir J 2014; 44: 1042-1054 Year: 2014 Potentiating and correcting mutant CFTR in patients with cystic fibrosis Source: Eur Respir Monogr 2014; 64: 129-149 Year: 2014 Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages Source: Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020 Year: 2021 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019 Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor Source: Eur Respir J 2016; 48: 249-252 Year: 2016 The CFTR and EGFR relationship in airway vascular growth, and its importance in cystic fibrosis Source: Eur Respir J 2013; 42: 1438-1440 Year: 2013 Nasal potential difference of carriers of the W493R ENaC variant with non-cystic fibrosis bronchiectasis Source: Eur Respir J 2016; 47: 322-324 Year: 2016 Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient Source: Eur Respir J 2002; 19: 374-376 Year: 2002 ANO1 expression and activity in cystic fibrosis Source: Annual Congress 2012 - New insights into airway epithelial cell physiology Year: 2012 Neomacrolides in cystic fibrosis Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease Year: 2012 Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019 Year: 2021